MeiraGTx Holdings plc Share Price & Technical Analysis
MGTX · $9.58 (+4.93%)
Healthcare / Biotechnology
$9.58
+4.93%
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xer…
Price chart
Seasonality
May has 1 positive and 2 negative years (last 5 years shown)
0% return in May, 1% avg return in past 3 year May month.
19% return in 2026, 24% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 0% | 19% | 5% | 0% | – | – | – | – | – | – | – | 19% |
| 25 | 2% | 15% | -4% | 6% | -28% | 25% | 18% | -4% | 12% | 11% | -8% | -2% | 42% |
| 24 | -13% | 0% | -2% | -18% | 0% | -14% | 24% | -21% | 2% | 31% | 21% | -10% | 0% |
| 23 | 27% | -8% | -33% | 2% | 30% | -3% | -6% | 2% | -23% | -6% | 16% | 35% | 31% |
| 22 | -37% | -5% | -3% | -26% | -18% | -10% | 8% | 1% | 2% | -14% | -15% | 7% | -111% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$902.13M
P/E ratio
—
52W high
$11.85
52W low
$4.82
Volume
7,78,732
Beta
1.24
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is MeiraGTx Holdings plc share price today?
- MeiraGTx Holdings plc (MGTX) last traded around $9.58 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MGTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MGTX. Download the app for real-time alerts.
- How can I analyze MeiraGTx Holdings plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.